As part of our environmental, social and governance (ESG) strategy, we continually strive toward better performance. This includes setting ambitious goals for our own operations, high expectations for our suppliers and an example of leadership for our industry. In the same way that it drives the development of our transformational medicines, innovation fuels our ESG strategy. Our strong governance profile includes board management and direct oversight by our Committee on Directors and Corporate Governance of ESG risks assessment and disclosure. This ensures our ability to operate with the highest levels of quality, integrity and ethics. Our ESG strategy is fully aligned to our corporate strategy and was developed based on an assessment of priority issues drawn from senior executives and key stakeholders. Our environmental and social programs focus on our critical risks and opportunities, with targets to accelerate innovation, enhance patient access to medicines, be an employer of choice and reduce our environmental footprint. We closed the year by announcing a new set of environmental goals for the coming decades and in 2021, the company plans to publish its first standards-aligned Environmental, Social and Governance report.
*Figures shown in infographic are 2019 metrics against 2015 baseline. (does not include former Celgene sites).